Vx-006 has completed preclinical development

VAXON-Biotech's second drug product, Vx-006, is a polypeptide composed of three optimized cryptic peptides derived from three different universal tumor antigens (MAGE, TERT, Her2/neu), presented in HLA-A2 patients. Indeed, targeting several peptides derived from different antigens will still enhance the global efficacy of cryptic peptides technology.

Vx-006 has completed preclinical development and will enter phase I trial in Q2-2013.